INTRODUCTION
============

Colonoscopy is an effective, and often preferred, method of colorectal cancer (CRC) screening that is widely endorsed by most major medical societies.[@b1-gnl-09-502]--[@b4-gnl-09-502] Removal of adenomatous polyps during colonoscopy can reduce the incidence of, and prevent death from, CRC.[@b5-gnl-09-502] Data from the Centers for Disease Control and Prevention show that CRC screening rates are increasing among persons aged 50 to 75 years, from 52.3% in 2002 to 65.4% in 2010.[@b6-gnl-09-502] Despite this important improvement, disparities in screening rates still exist. In 2012, 69.6% of Whites compared to 66.1% of African Americans age 50 and older ever had a screening colonoscopy (SC) or sigmoidoscopy. Rates were lower among Hispanics (56.8%) and persons with income less than US \$15,000 per year (53.8%).[@b7-gnl-09-502] For uninsured individuals, screening rates are particularly low. In one study, rates of 35.6% were reported,[@b8-gnl-09-502] and another found that only 33% of uninsured patients had undergone any test for CRC screening compared to 77% of insured patients.[@b9-gnl-09-502] Lack of health insurance is associated with worse outcomes with regard to cancer screening and treatment.[@b10-gnl-09-502]--[@b13-gnl-09-502] In part, this is due to the fact that uninsured and Medicaid patients may present with later stage disease or complications of CRC.[@b14-gnl-09-502],[@b15-gnl-09-502] Thus, increasing screening rates among the uninsured, minorities, and persons from lower socioeconomic status (SES) remains an important goal.

In recent years, two general interventions were developed to increase screening colonoscopy rates: direct-access endoscopies (DAE) and Patient Navigator (PN) programs. Under a DAE system, primary care physicians refer patients directly for colonoscopy (based on specific clinical guidelines) without a preprocedure visit to the gastroenterologist or anesthesiologist.[@b16-gnl-09-502] Potential benefits of DAE include: saving time and cost, and minimizing time taken off from work.[@b17-gnl-09-502] PNs are healthcare professionals trained to guide a patient through the process of obtaining colonoscopy after the initial physician referral by assisting with scheduling, transportation, answering questions, and providing appointment reminders.[@b18-gnl-09-502] For the past decade, at our institution, we have implemented a program designed to increase SC rates among our urban minority population. Using DAE with PN, we demonstrated increased SC, fecal occult blood testing, and flexible sigmoidoscopy rates among African American and Hispanic patients.[@b19-gnl-09-502]--[@b21-gnl-09-502] In those studies, most patients had some form of health insurance, mainly public insurance (Medicare or Medicaid).

In 2004, the New York City Council authorized funding for SC for uninsured and underinsured New Yorkers over age 50.[@b22-gnl-09-502] These funds, administered through the American Cancer Society, were made available in the form of grants to hospitals in the New York City area interested in performing SC for a discounted fee. We have been participating in this program for the past 8 years. The present report describes the results of our institution's efforts to provide SC to a group of predominately minority, uninsured and underinsured patients through this program.

MATERIALS AND METHODS
=====================

1. Patient eligibility
----------------------

Patients eligible for enrollment in our screening program were men and women age ≥50 who had a referral for a SC from their primary care physician, and who met clinical criteria for SC (e.g., had no gastrointestinal symptoms). Eligible patients also met the following criteria: they could not (1) have fecal occult blood test within the past year or (2) have flexible sigmoidoscopy within the past 5 years, (3) have colonoscopy within the past 10 years, (4) have a history of inflammatory bowel disease, (5) have personal history of CRC, (6) speak languages other than English or Spanish, (7) be at greater than average CRC risk, and (8) have insurance or sufficient funds to cover the cost of the SC.

2. Patient recruitment
----------------------

Eligible patients were identified by their provider from primary care clinics at The Mount Sinai Hospital (Internal Medicine Associates, Med-Peds Clinic, Ob/Gyn clinic, East Harlem Health Outreach Partnership) and other local community health centers based on review of their chart and the above criteria. The providers provided information on the patient's past medical history, whether the patient was taking aspirin, nonsteroidal anti-inflammatory medications, or anticoagulants. This information was forwarded to a gastrointestinal nurse or gastroenterologist who reviewed the information and determined whether the patient was an appropriate candidate for DAE and if so, selected an appropriate bowel preparation. This information was then given to a PN to begin scheduling the patient for SC.

3. PN
-----

All patients in our study received the assistance of a PN. The PNs were bilingual (Spanish-English) health educators who guided the patient through the process of getting their SC from the time of their referral through completion. Upon receiving the accepted referral, the PN contacted the patient by phone to review their medical history and current medications. The PN educated the patient on the process of the SC and CRC risk factors and prevention, answered questions, addressed fears about the procedure, and scheduled the procedure. If necessary, the PN also helped arrange for transportation. Written instructions in the patient's preferred language (English or Spanish) for bowel preparation and procedure date were mailed to the patient's home. This was followed by a reminder postcard with the time and location of their appointment. The PN contacted patients again by phone both 2-weeks and 3-days prior to their colonoscopy, at which time they would: provide appointment reminders, review written instructions and bowel preparation, provide details on what would happen on the day of the procedure, and to answer questions.

4. Data analysis
----------------

A secure database of all patients was created, including name, self-described ethnicity, date of first contact by the PN, date of scheduled SC, and SC outcome (completion and findings). Ethnicity was categorized as Hispanic, African American, White, or Other. Following completion of the colonoscopy, each colonoscopy report was reviewed to determine completeness of the exam, any abnormal findings, and quality of the bowel preparation. Pathology reports were then reviewed (by T.H.C.) and analyzed for histological type, size, and location of any polyps that were found. A second reviewer (S.H.I.) confirmed proper classification of polyps. Data was analyzed using SPSS software version 20 for Windows (SPSS Inc., Chicago, IL, USA). We used descriptive statistics to tabulate the demographics of the study population, polyp type, and location. Adenomatous polyps were further described in terms of adenoma size, histology, dysplasia, and multiplicity. Chi-square tests were used to compare ethnicity with the colonoscopy findings. All tests of significance were two-sided with a p\<0.05.

RESULTS
=======

1. Patient selection
--------------------

Between April 2004 and June 2011, a total of 493 patients were referred for SC via our DAE program and a total of 222 patients completed screening colonoscopies at our facility ([Fig. 1](#f1-gnl-09-502){ref-type="fig"}).

2. Patient demographics
-----------------------

[Table 1](#t1-gnl-09-502){ref-type="table"} shows the demographic breakdown of the study patients by gender, ethnicity, and insurance status. Of the 222 uninsured or underinsured patients, the vast majority were uninsured (n=209, 94.1%); 13 underinsured patients had public health insurance (Medicaid or Medicare HMO) but were eligible for our program because their insurance was inactive, limited, or the patient could not afford their copayment.

A comparison of the demographics of patients who had polyps on SC (n=47) versus those without any polyps (n=175) revealed no difference in mean age or ethnicity between the two groups ([Table 2](#t2-gnl-09-502){ref-type="table"}).

Information on quality of bowel preparation was available for 207 patients. Of those, bowel preparation was rated excellent in 49 (23.7%), very good in 27 (13.0%), good in 115 (55.6%), fair in 12 (5.7%), and poor in 4 (2.0%).

3. Colonoscopy findings
-----------------------

Colonoscopy findings by gender, ethnicity, and age are summarized in [Table 3](#t3-gnl-09-502){ref-type="table"}. There were no sessile serrated polyps detected in this cohort. Adenoma location was categorized as either proximal or distal to the splenic flexure. There was no statistically significant difference in polyp type or location in terms of ethnicity.

Among the 31 patients who were found to have adenomas, the majority had single (90%), tubular adenomas (84%) with low grade dysplasia (94%). Adenoma rates were highest among African Americans (24.3%) compared to Hispanics (12.1%) and Whites (11.6%). Overall, 10 of 222 (4.5%) patients screened were found to have adenomas with advanced pathology (AAP) defined as an adenoma ≥1 cm in diameter, villous/tubulovillous histology, high-grade dysplasia, or cancer (regardless of size). Half of all AAP were tubulovillous, four of 10 (40%) were located in the proximal colon. No cancers were detected, but two AAP had high grade dysplasia. There were no statistically significant differences among the three ethnic groups in terms of rate of adenoma, location, size, number, degree of dysplasia, or presence of AAP.

In terms of age, patients ≥60 years old had significantly more AAP than patients \<60 (8.6% vs 2.6%, p=0.047). Age was not a significant predictor of adenoma prevalence, degree of dysplasia, or size. No significant differences in polyp type, location, adenoma or AAP rate, were found based on gender.

DISCUSSION
==========

Our study focused on the SC findings of a group of primarily uninsured, low SES urban minority patients. Among 493 patients referred for screening colonoscopy, fully half (n=245, 50%) were either inappropriate referrals, canceled or did not show up for their appointment and therefore did not receive SC. Although we do not have exact data on how many of these 245 patients were inappropriate referrals, we suspect that many were not screened because either the referrals were incomplete, or the patients did not meet criteria for SC. One of the drawbacks of a DAE system may be an increase in inappropriate referrals for SC.[@b23-gnl-09-502] However, of the remaining 248 patients, 222 patients (90%) completed their colonoscopy, indicating that SC can be successfully accomplished in the context of an organized, programmatic effort.

Our screening program detected clinically significant pathology. Specifically, 24.3% of African Americans, 12.1% of Hispanics, and 11.6% of Whites had adenomas detected and removed. Moreover, 10.8% of African Americans, 3.5% of Hispanics, and 2.3% of Whites had adenomas with advanced pathology. In our earlier DAE/PN study consisting of mostly minority patients with health insurance, we found a relatively lower adenoma rate in African Americans and a higher rate among Hispanics. In that study, 12% African Americans, 19% Hispanics, and 11% other patients had adenomas and rates of AAP were similar in each group (approximately 2%).[@b21-gnl-09-502] In a more recent, larger prospective cohort trial of over 500 Black and Hispanic individuals, we found that the overall prevalence of adenomas and proximal adenomas were 26.4% and 20%, respectively. Advanced adenomas occurred in 12.2% Blacks and 10.8% Hispanics.[@b24-gnl-09-502]

[Table 4](#t4-gnl-09-502){ref-type="table"} provides a comparison of our data with other studies in minority individuals. The combined data indicate that ethnic minorities have premalignant colorectal pathology at rates that are at least as high as that of Whites.[@b21-gnl-09-502],[@b24-gnl-09-502]--[@b33-gnl-09-502] Our findings among African American patients differ from some of the earlier, larger studies, that suggests a higher prevalence of adenomas, AAP, and proximal polyps than was found in our group of African Americans.[@b27-gnl-09-502]--[@b29-gnl-09-502] We suspect that these differences may be partially explained by our smaller sample size.

We found similar prevalence of polyps and adenomas between Hispanic and White patients, which is consistent with other studies showing similar or lower risk of adenomas in Hispanics.[@b30-gnl-09-502]--[@b33-gnl-09-502]

When examining the groups by age, we found that patients age 60 and older had a higher rate of AAP compared to patients younger than 60. This is consistent with data suggesting that adenoma detection and probability of developing advanced colorectal neoplasia increases with age.[@b34-gnl-09-502],[@b35-gnl-09-502]

Because of the barriers related to SC, it has been assumed that it would be difficult to execute a SC program among uninsured patients. Over the past decade, we have had considerable success getting a similar population of minority individuals of low SES who had mostly public insurance to complete colonoscopy. We showed that PNs increased SC compliance, which was associated with higher patient satisfaction.[@b19-gnl-09-502]--[@b21-gnl-09-502],[@b36-gnl-09-502] Moreover, a cost analysis of our program found that use of PNs among our patients with mostly public health insurance generated a net increase in income, mainly by increasing colonoscopy completion rates.[@b37-gnl-09-502] These results were in keeping with other trials that showed that use of PNs was associated with higher SC completion rates and better preparation quality among low income minority patients with health insurance.[@b38-gnl-09-502]--[@b42-gnl-09-502] Indeed, we observed very low fair or poor bowel preparation rates in the present study. This implies that use of PNs can help circumvent at least some of the barriers to obtaining SC in patients with health insurance, and our findings herein extend this observation to the uninsured.

Patients in this study had their SC funded through the New York City Council, partnered with the American Cancer Society. This funding was part of a larger campaign launched in 2004 by New York City Department of Health and Mental Hygiene, together with the Citywide Colon Cancer Control Coalition (C5 Coalition) to increase SC in underserved populations. A recent study looking at rates of SC among New Yorkers during the first 5 years of this campaign found that timely colonoscopy screening increased from 41.7% to 61.7% overall.[@b43-gnl-09-502] Furthermore, racial and ethnic disparities improved to the point where rates of SC became similar among Whites, African Americans, Hispanics, men, and women. However, whereas screening rates among the uninsured also improved (from 15% to 43.3%), they continue to lag behind patients with private insurance, Medicare, and Medicaid who had screening rates of 66.8%, 61.4%, and 60.4%, respectively. Thus, uninsured patients are still lagging behind insured patients when it comes to CRC screening via colonoscopy.

Targeted funding for SC (for example, in the form of grants) may be one way to help address this continued disparity. Elmunzer *et al*.[@b44-gnl-09-502] recently reported on a flexible sigmoidoscopy-based CRC screening "health fair" for uninsured patients. Using a standard health clinic converted into an endoscopy suite, they were able to screen 52 patients at a cost of US \$126 per patient.[@b44-gnl-09-502] Dimase *et al*.[@b45-gnl-09-502] reported on early efforts to provide no-cost SC and PN to underserved patients in Rhode Island using a coalition of participating endoscopists. This provides examples of how medical philanthropy may help address the low rates of CRC screening among the uninsured. A more broad overview of CRC screening approaches and issues in underserved populations has been recently published.[@b46-gnl-09-502]

Our study has a number of limitations. Our patient sample size is relatively small, potentially limiting the power to find pathological differences that might have been detected with a larger sample. Our cohort consisted of mostly uninsured minority patients from a relatively narrow geographic area in New York City, so results may not generalize to other populations. Recruitment of patients took place over several years, and we do not have exact figures on which patients did not complete SC because they either did not show up for, or canceled their appointment, lacked essential data, or had a contraindication. Despite these limitations, we found significant pathology among our patient population. Further research is needed to better understand the distribution and pathology of colorectal polyps in uninsured patients.

This study was funded by a grant from the American Cancer Society.
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###### 

Patient Demographics (N=222)

  Demographics        Value
  ------------------- ------------
  Age, yr             57.0±6.4
  Gender              
   Female             122 (55.0)
   Male               100 (45.0)
  Ethnicity           
   African American   37 (16.6)
   Hispanic           141 (63.5)
   White              43 (19.4)
   Other              1 (0.5)
  Insurance status    
   Uninsured          209 (94.1)
   Underinsured       13 (5.9)

Data are presented as mean±SD or number (%).

###### 

Demographics of Patients with and without Polyps

                      With polyps (n=47)   Without polyps (n=175)   p-value
  ------------------- -------------------- ------------------------ -------------------------------------------------
  Age, yr             57.6±6.0             57.2±6.2                 NS[\*](#tfn4-gnl-09-502){ref-type="table-fn"}
  Gender                                                            
   Female             20 (43)              102 (58)                 0.054[†](#tfn5-gnl-09-502){ref-type="table-fn"}
   Male               27 (57)              73 (42)                  
  Ethnicity                                                         
   African American   14 (30)              23 (13.1)                0.053[‡](#tfn6-gnl-09-502){ref-type="table-fn"}
   Hispanic           26 (55)              115 (65.7)               
   White              7 (15)               36 (20.6)                
   Other              0                    1 (0.6)                  

Data are presented as mean±SD or number (%).

NS=not significant.

Analysis of variance test;

Comparison of gender between patients with polyps and patients without polyps (χ^2^=3.704);

Comparison of ethnicity between patients with polyps and patients without polyps (χ^2^=7.674).

###### 

Colonoscopy Findings

                                                               Total patients (n=222)   Gender      Ethnicity   Age                                                                        
  ------------------------------------------------------------ ------------------------ ----------- ----------- ------- ----------- ----------- ---------- ------- ----------- ----------- -------
  Patients with polyps                                         47 (21.2)                20 (16.4)   27 (27.0)   0.054   14 (37.8)   26 (18.4)   7 (16.3)   0.053   30 (19.7)   17 (24.3)   0.441
  Type of polyp                                                                                                                                                                            
   Adenoma                                                     31 (14.0)                14 (11.5)   17 (17.0)   0.368   9 (24.3)    17 (12.1)   5 (11.6)   0.734   19 (12.5)   12 (17.1)   0.714
   Hyperplastic                                                6 (2.7)                  2 (1.6)     4 (4.0)             2 (5.4)     3 (2.1)     1 (2.3)            5 (3.3)     1 (1.4)     
   Other                                                       10 (4.5)                 4 (3.3)     6 (6.0)             3 (8.1)     6 (4.3)     1 (2.3)            6 (3.9)     4 (5.7)     
  Adenoma location                                                                                                                                                                         
   Proximal                                                    15 (6.8)                 6 (4.9)     9 (9.0)     0.426   4 (10.8)    10 (7.1)    1 (2.3)    0.568   9 (5.9)     6 (8.6)     0.421
   Distal                                                      15 (6.8)                 7 (5.7)     8 (8.0)             5 (13.5)    6 (4.3)     4 (9.3)            10 (6.6)    5 (7.1)     
   Proximal and distal                                         1 (0.5)                  1 (0.8)     0                   0           1 (0.7)     0                  0           1 (1.4)     
  Adenoma multiplicity                                                                                                                                                                     
   1 adenoma                                                   28 (12.6)                12 (9.8)    16 (16.0)   0.365   8 (21.6)    16 (11.3)   4 (9.3)    0.560   17 (11.2)   11 (15.7)   0.636
   \>1 adenoma                                                 3 (1.4)                  2 (1.6)     1 (1.0)             1 (2.7)     1 (0.7)     1 (2.3)            2 (1.3)     1 (1.4)     
  Adenoma histology                                                                                                                                                                        
   Tubular                                                     26 (11.7)                10 (8.2)    16 (16.0)   0.115   6 (16.2)    15 (10.6)   5 (11.6)   0.202   16 (10.5)   10 (14.3)   0.649
   Tubulovillous                                               5 (2.3)                  4 (3.3)     1 (1.0)             3 (8.1)     2 (1.4)     0                  3 (2.0)     2 (2.9)     
  Adenoma degree of dysplasia                                                                                                                                                              
   Low-grade                                                   29 (13.1)                13 (10.7)   16 (16.0)   0.493   9 (24.3)    16 (11.3)   4 (9.3)    0.375   19 (12.5)   10 (14.3)   0.101
   High-grade                                                  2 (0.9)                  1 (0.8)     1 (1.0)             0           1 (0.7)     1 (2.3)            0           2 (2.9)     
  Adenoma size, cm                                                                                                                                                                         
   ≤0.5                                                        13 (5.9)                 4 (3.3)     9 (9.0)     0.408   2 (5.4)     8 (5.7)     3 (7.0)    0.732   9 (5.9)     4 (5.7)     0.444
   0.6--0.9                                                    10 (4.5)                 6 (4.9)     4 (4.0)             4 (10.8)    4 (2.8)     2 (4.7)            7 (4.6)     3 (4.3)     
   1.0--1.9                                                    5 (2.3)                  2 (1.6)     3 (3.0)             2 (5.4)     3 (2.1)     0                  2 (1.3)     3 (4.3)     
   ≥2.0                                                        3 (1.4)                  2 (1.6)     1 (1.0)             1 (2.7)     2 (1.4)     0                  1 (0.7)     2 (2.9)     
  Advanced adenoma[†](#tfn9-gnl-09-502){ref-type="table-fn"}   10 (4.5)                 5 (4.1)     5 (5.0)     0.747   4 (10.8)    5 (3.5)     1 (2.3)    0.236   4 (2.6)     6 (8.6)     0.047
  Advanced adenoma location                                                                                                                                                                
   Proximal                                                    4 (1.8)                  1 (0.8)     3 (3.0)     0.409   1 (2.7)     3 (2.1)     0          0.407   1 (0.7)     3 (4.3)     0.099
   Distal                                                      6 (2.7)                  4 (3.3)     2 (2.0)             3 (8.1)     2 (1.4)     1 (2.3)            3 (2.0)     3 (4.3)     

Data are presented as number (%).

The one patient with ethnicity listed as "Other" had a normal colonoscopy and is not listed separately in this table;

Advanced adenoma defined as an adenoma ≥1 cm in diameter or any adenoma (regardless of size) with villous histology, high-grade dysplasia, or cancer.

###### 

Colonoscopy Findings from Earlier Studies

  Study                                                                            Study type      Adenoma or polyp prevalence by ethnicity, %       Polyp distribution, %   AAP prevalence, %   Study population demographics                                                                                                                
  -------------------------------------------------------------------------------- --------------- ------------------------------------------------- ----------------------- ------------------- ------------------------------- -------------------------------------------------- -------------------------------------------------- ------ --------------------------------------------------------------
  Current study                                                                    Prospective     14.0                                              24.3                    12.1                11.6                            7.7[\*](#tfn11-gnl-09-502){ref-type="table-fn"}    9.9[\*](#tfn11-gnl-09-502){ref-type="table-fn"}    4.5    Uninsured; African American (37), Hispanic (141), White (43)
  Chen *et al*.[@b21-gnl-09-502]                                                   Prospective     16.4                                              12.0                    19.0                11.0                            8.8[\*](#tfn11-gnl-09-502){ref-type="table-fn"}    20.3[\*](#tfn11-gnl-09-502){ref-type="table-fn"}   2.0    African American (98), Hispanic (211), Others (44)
  Lee *et al*.[@b24-gnl-09-502]                                                    Prospective     26.4                                              24.8                    27.7                NA                              20.2                                               NA                                                 11.5   African American (270), Hispanic (314)
  Kanna *et al*.[@b25-gnl-09-502]                                                  Retrospective   14.5                                              NA                      NA                  NA                              53.2[†](#tfn12-gnl-09-502){ref-type="table-fn"}    46.8[†](#tfn12-gnl-09-502){ref-type="table-fn"}    4.3    African American (485), Hispanic (3,475)
  Lebwohl *et al*.[@b26-gnl-09-502]                                                Retrospective   20.3                                              26.0                    22.0                19.0                            9.2[\*](#tfn11-gnl-09-502){ref-type="table-fn"}    NA                                                 4.4    African American (591), Hispanic (942), White (3,542)
  Rex *et al*.[@b27-gnl-09-502]                                                    Prospective     35.0                                              35.0                    NA                  NA                              65.3[†](#tfn12-gnl-09-502){ref-type="table-fn"}    34.7[†](#tfn12-gnl-09-502){ref-type="table-fn"}    2.5    African Americans (121)
  Thornton *et al*.[@b28-gnl-09-502],[‡](#tfn13-gnl-09-502){ref-type="table-fn"}   Prospective     37.8                                              35.0                    NA                  38.0                            20.1[\*](#tfn11-gnl-09-502){ref-type="table-fn"}   18.7[\*](#tfn11-gnl-09-502){ref-type="table-fn"}   NA     African Americans (3,195)
  Nouraie *et al*.[@b29-gnl-09-502]                                                Retrospective   83.9[†](#tfn12-gnl-09-502){ref-type="table-fn"}   NA                      NA                  NA                              36.1[†](#tfn12-gnl-09-502){ref-type="table-fn"}    34[†](#tfn12-gnl-09-502){ref-type="table-fn"}      NA     90% African American (review of 5,013 colorectal polyps)
  Thoma *et al*.[@b30-gnl-09-502]                                                  Retrospective   47.0                                              NA                      45.0                48.0                            19[\*](#tfn11-gnl-09-502){ref-type="table-fn"}     NA                                                 4.0    Hispanic (607), White (1,251)
  Zheng *et al*.[@b33-gnl-09-502]                                                  Retrospective   19.0                                              21.9                    14.8                24.0                            45[†](#tfn12-gnl-09-502){ref-type="table-fn"}      42[†](#tfn12-gnl-09-502){ref-type="table-fn"}      NA     African American (635), Hispanic (738), White (283)

AAP, adenomas with advanced pathology; NA, not applicable.

As percentage of total patients;

As percentage of total polyps;

Data for polyp histological subtype not available.
